Eisai launches LEQEMBI for early Alzheimer’s disease treatment in IndiaEisai has launched LEQEMBI (lecanemab) in India after receiving CDSCO approval, introducing the country's first disease-modifying therapy for early Alzheimer's disease. In India, LEQEMBI is indicated for patients with Mild Cognitive Impairment (MCI) and mild dementia due to early Alzheimer’s disease, marking the introduction of this first-of-its-kind Disease-Modifying Therapy (DMT) in the country’s Alzheimer’s disease treatment landscape, the pharma company said in a statement on Monday. LEQEMBI (lecanemab) is a humanised monoclonal antibody that selectively targets aggregated amyloid-beta, enabling its clearance while reducing further deposition. “What is promising about LEQEMBI (lecanemab) is its ability to intervene early in the disease process,” said Ritesh Jain, Head of Commercial Operations, Eisai India. Access and awareness remain critical barriers in Alzheimer’s disease care in India.